Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
| Active as of 2023-12-17 |
Resource Evidence "179635" Version "4" Updated "2023-12-03 09:56:07+0000"
Profile: ComparativeParticipantFlow
StructureDefinition Work Group: cds
url: https://fevir.net/resources/Evidence/179635
identifier: FEvIR Object Identifier: 179635
version: 1.0.0-ballot
name: ComparativeParticipantFlow_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial
title: ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
status: active
date: 2023-12-17 16:55:23+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
author: Brian S. Alper:
| Code | Value[x] |
| Evidence Communication (Details: https://fevir.net/resources/CodeSystem/179423 code evidence-communication = 'Evidence Communication', stated as 'Evidence Communication') | ComparativeParticipantFlow (Evidence Based Medicine on FHIR Implementation Guide Code System#ComparativeParticipantFlow) |
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | Citation | ResourceReference |
| cite-as | ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Evidence]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2023-11-27. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635. | |
| derived-from | Citation/179637: 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal |
description: Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial
variableDefinition
VariableDefinitionVariableRoleCode: population
description: Participants in the opioid detoxification trial
note: population
variableRole: Use extension:variableRoleCode instead. (EvidenceVariableRole#population "population")
variableDefinition
VariableDefinitionVariableRoleCode: exposure
VariableDefinitionComparatorCategory: false
description: GroupAssignment: Lofexidine vs. Placebo
note: exposure
variableRole: Use extension:variableRoleCode instead. (EvidenceVariableRole#exposure "exposure")
variableDefinition
VariableDefinitionVariableRoleCode: outcome
description: Dropout due to stopping intervention
note: outcome
variableRole: Use extension:variableRoleCode instead. (EvidenceVariableRole#measuredVariable "measured variable")
observed: EvidenceVariable/179636: PartiicipantFlowMeasure: Dropout due to stopping intervention "ParticipantFlowMeasure_Dropout_due_to_stopping_intervention"
statistic
description: 18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)
statisticType: Risk Ratio (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#STATO:0000245)
quantity: 1.59
numberAffected: 30
SampleSizes
NumberOfParticipants 68 AttributeEstimates
Description Type Quantity p < 0.01 P-value (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#TBD:0000076) <0.01
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change